" Paul Bisaro

Actavis to buy U.S. rival Warner Chilcott for $5 billion
ZUG, Switzerland,[url=http://www.fbrecs.com/]jimmy choo outlet[/url], May 20 () -- Swiss generic drug producer Actavis said it would buy U.S. rival Warner Chilcott for a deal valued at $5 billion.It is an all-stock deal that provides a premium 5 percent on Warner Chilcott's closing price Friday. Actavis said in a release it agreed to pay 0.16 of a share for each Warner Chilcott share, which comes to $20.08 per share.Actavis will assume Warner Chilcott's $3.5 billion long-term debt, as well, The New York Times reported."We have set as our strategic corporate objective to build a leading global specialty pharmaceutical company," Paul Bisaro, Actavis' chief executive, said in a statement. Anecdotes back that up. Last month,[url=http://www.fbrecs.com/]Jimmy Choo Sale[/url], talks to have Actavis sell itself to Valeant Pharmaceuticals collapsed. Meanwhile, the Actavis board turned down offers from others, including Mylan, a source told the Times.Bisaro said Actavis and Warner Chilcott together "creates a strong specialty brand portfolio focused in therapeutic categories with strong growth potential.""And [it] is supported by a deep pipeline of development programs," he said.

The post has been approved 0 times